Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental cell shot aims to tame failing livers

NCT ID NCT07488546

First seen Apr 13, 2026 · Last updated May 22, 2026 · Updated 6 times

Summary

This early-stage trial tests a single injection of HCL001 cells in 39 adults with decompensated cirrhosis, a severe form of liver disease. The main goal is to check safety and find the right dose, with early signs of effectiveness also measured. Participants must have a diagnosis of cirrhosis from causes like hepatitis or alcohol use, and be in fair overall health. This is not a cure, but aims to control the disease and improve liver function.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DECOMPENSATED CIRRHOSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospita

    Shanghai, Shanghai Municipality, China

Conditions

Explore the condition pages connected to this study.